Cardinal Health (CAH) Emerged as a Key Contributor on Pharmaceutical Strength and Margin Expansion

Core Insights - Renaissance Investment Management's Q4 2025 "Large Cap Growth Strategy" underperformed compared to the S&P 500 and Russell 1000 Growth Index, with the S&P 500 gaining 2.7% during the quarter [1] - The broader market remained weak, with nearly 60% of Russell 1000 Growth constituents posting negative returns, despite a rally in equities for three consecutive quarters [1] - Portfolio performance was bolstered by holdings benefiting from AI infrastructure, semiconductor equipment, and resilient healthcare distribution trends, while declines were noted in financial technology, cloud software, media streaming, transportation, and communications equipment sectors [1] Company-Specific Insights - Cardinal Health, Inc. (NYSE:CAH) is highlighted as a key holding, distributing pharmaceuticals and medical products, with a one-month return of -8.33% and a market capitalization of approximately $48.76 billion [2] - Cardinal Health's stock traded between $120.72 and $233.60 over the last 52 weeks, closing at around $207.23 per share on March 24, 2026 [2]